34 completed, 4 unknown, 2 recruiting, 2 terminated. 45 Phase 2, 9 Phase 1, 5 Phase 3.
Follow Tetanus: new trials by email Literature Review of Tetanus trials Research Report on Tetanus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Tdap vaccine, Placebo - Pertussis (Whooping Cough), Diphtheria | Phase 2 | Recruiting | Changchun BCHT Biotechnology Co. | 420 | 2026-08-12 | 2026-10-26 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants SNA02-48, Placebo, HTIG - Tetanus | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 255 | 2025-04-28 | 2026-06-03 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | CanSino Biologics Inc. | 1820 | 2024-12-20 | 2026-08-26 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 2 | Completed | ABO Holdings, Inc. | 107 | 2023-05-05 | 2026-07-02 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults GR2001, Placebo, HTIG - Tetanus | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 202 | 2023-03-04 | 2024-03-08 |
| Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers TNM002 (low dose), TNM002 (medium dose), TNM002 (high dose) - Tetanus | Phase 2 | Completed | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 240 | 2022-04-18 | 2025-09-16 |
| Tdap Vaccine Safety for Plasma Donors Adacel - Tetanus | Phase 2 / Phase 3 | Completed | GCAM Inc. | 110 | 2020-02-03 | 2022-12-06 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults GC3111 vaccine, Boostrix® vaccine - Tetanus, Diphtheria | Phase 2 | Unknown | Green Cross Corporation | 213 | 2019-10-14 | 2020-01-23 |
| A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS RSV Vaccine, Tdap, Placebo - Respiratory Tract Infection | Phase 2 | Completed | Pfizer | 713 | 2019-10-01 | 2021-02-15 |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td) - Glioblastoma | Phase 2 | Terminated | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 6 | 2019-09-30 | 2024-04-08 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide - Clostridium Difficile Immunisation, Diphtheria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 399 | 2019-01-24 | 2025-05-21 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| A Study of AV0328 Administered to Healthy Adult Volunteers AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3 - PNAG-expressing Pathogenic Microbes Vaccine | Phase 1 / Phase 2 | Completed | Alopexx Vaccine, LLC | 16 | 2017-03-22 | 2019-03-19 |
| Intrathecal Tetanus Immunoglobulin to Treat Tetanus Human tetanus immunoglobulin, Intramuscular antitoxin - Tetanus | Phase 1 / Phase 2 | Completed | Oxford University Clinical Research Unit, Vietnam | 272 | 2017-02-13 | 2020-05-29 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
Showing 20 of 45. Sign in to see all of them.
Diphtheria (35) · Hepatitis B (23) · Whooping Cough (22) · Poliomyelitis (21) · Haemophilus Infections (19) · Glioblastoma (1) · Influenza, Human (1) · Malaria (1) · Meningitis, Meningococcal (1) · Respiratory Tract Infections (1)
Bacterial Infections (45) · Bacterial Infections and Mycoses (45) · Clostridium Infections (45) · Gram-Positive Bacterial Infections (45) · Infections (45) · Actinomycetales Infections (35) · Corynebacterium Infections (35) · Gram-Negative Bacterial Infections (33) · Virus Diseases (26) · Respiratory Tract Diseases (24) · Blood-Borne Infections (23) · Communicable Diseases (23) · DNA Virus Infections (23) · Digestive System Diseases (23) · Hepadnaviridae Infections (23)
Tetanus Toxoid (10) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9) · Poliovirus Vaccine, Inactivated (4) · Vaccines, Combined (4) · 13-valent pneumococcal vaccine (3) · Diphtheria-Tetanus-acellular Pertussis Vaccines (3) · adacel (3) · Boostrix (2) · Hepatitis B Vaccines (2) · 10-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Drug Evaluation (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1)
GlaxoSmithKline (16) · Sanofi Pasteur, a Sanofi Company (5) · LG Chem (4) · Green Cross Corporation (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ABO Holdings, Inc. (1) · Alopexx Vaccine, LLC (1) · CanSino Biologics Inc. (1) · Centers for Disease Control and Prevention (1) · Changchun BCHT Biotechnology Co. (1) · GCAM Inc. (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Mustafa Khasraw, MBChB, MD, FRCP, FRACP (1) · Oxford University Clinical Research Unit, Vietnam (1)
United States (10) · China (7) · Philippines (6) · Finland (4) · Canada (3) · South Korea (3) · Dominican Republic (2) · Germany (2) · Poland (2) · Argentina (1) · France (1) · Iran (1) · Japan (1) · Kenya (1) · Mali (1)
Adam Thaler, DO (1) · Edison Alberto, MD (1) · Hal Landy, MD (1) · Hanqing He (1) · Jiawei Xu (1) · Jie Hou (1) · Jing Zhang, PHD (1) · Josefina Carlos, MD (1) · Joshua A Mott, PhD (1) · Marc-Alain Widdowson, VetMB, MSc (1) · Meredith L McMorrow, MD, MPH (1)
PMID 20657177, PMID 28340322, PMID 21372751, PMID 23241989, PMID 24341659, PMID 24346596, PMID 25540274, PMID 30809591, PMID 34637519, PMID 35561721, PMID 38586589
2009 (1), 2016 (1)